Publications
169
Citations
7,805
Est. group size
~1
Recurring co-author estimate
Active years
25
Publishing since 2002
Jared R. Brosch conducts clinical and translational research on Alzheimer's disease and related cognitive disorders. The work spans clinical trials of experimental drugs (such as anti-amyloid antibodies and RNA-interference therapies), brain imaging to track disease markers, and strategies for detecting cognitive decline earlier in patient care. Studies often involve genetically inherited (familial) forms of Alzheimer's disease.
Publication activity has been steady to growing over the past decade, averaging about 10 papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
No award with a current end date on record.
1 earlier award
- NIH P30AG072976Sep 2021 – Jun 2026 · $683k awarded
Clinical Core
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~15 · 15% small-team papers (≤3 authors) · across 30 venues
- Retraction notice to “Generation of a gene-corrected human isogenic iPSC line from an Alzheimer’s disease iPSC line carrying the PSEN1 H163R mutation” [Stem Cell Res. 79 (2024) 103495]
Stem Cell Research · 2026
- Towards Identifying an Optimal Time for Amyloid Assessment with Donanemab Treatment (S23.004)
Neurology · 2025
- Multiple‐Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid‐Beta Precursor Protein for Alzheimer’s Disease
Alzheimer s & Dementia · 2025
- Implementing early detection of cognitive impairment in primary care to improve care for older adults
Journal of Internal Medicine · 2025
- Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease
Alzheimer s Research & Therapy · 2025
- RETRACTED: Generation of a gene-corrected human isogenic iPSC line from an Alzheimer’s disease iPSC line carrying the PSEN1 H163R mutation
Stem Cell Research · 2024
- Single ascending dose results from an ongoing Phase 1 study of mivelsiran (ALN‐APP), the first investigational RNA interference therapeutic targeting amyloid precursor protein for Alzheimer’s disease
Alzheimer s & Dementia · 2024
- Implementing Digital Cognitive Assessments to Detect Cognitive Impairment: Results from the Davos Alzheimer’s Collaborative Early Detection Program
Alzheimer s & Dementia · 2024
- Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials
The Journal of Prevention of Alzheimer s Disease · 2024
- Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer’s disease
Brain · 2023
- Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer’s disease
European Journal of Nuclear Medicine and Molecular Imaging · 2023
- Donanemab in Early Symptomatic Alzheimer Disease
JAMA · 2023
- Interim phase 1 part A results for ALN‐APP, the first investigational RNAi therapeutic in development for Alzheimer’s disease
Alzheimer s & Dementia · 2023
- Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid
Nature · 2022
- Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study
The Lancet Neurology · 2022
- Alzheimer s & Dementia×41
- medRxiv×5
- The Lancet Neurology×3
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring×3
- Nature Communications×3
- Liana G. Apostolova
Medicine · Indiana University
- Shannon L. Risacher
Medicine · Indiana University
- Maria Kataki
Medicine · The Ohio State University
- Chad Ward
Medicine · University of Michigan
- Kelley Faber
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile